Jiro Ichikawa*, Jonathan G. Schoenecker, Rikito Tatsuno, Tomonori Kawasaki, Katsue Suzuki-Inoue and Hirotaka Haro Pages 1009 - 1012 ( 4 )
Coagulation activation is associated with cancer progression and morbidity. Recently, mechanisms through which coagulation proteases drive the tumor microenvironment (TME) have been elucidated. This review aims to develop a new strategy dependent on the coagulation system for treating osteosarcoma (OS). We focused on tissue factor (TF), the main initiator of the extrinsic coagulant pathway, as a target for OS treatment. It was found that cell surface-TF, TF-positive extracellular vesicles, and TF-positive circulating tumor cells could drive progression, metastasis, and TME in carcinomas, including OS. Thus, targeting tumor-associated coagulation by focusing on TF, the principle catalyst of the extrinsic pathway, TF is a promising target for OS.
Osteosarcoma, tissue factor, tumor microenvironment, chemotherapy, antibody-drug-conjugate, heparin, low molecular weight heparin.